Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M118 vs Unfractionated Heparin in Stable CAD Undergoing PCI
NCT00543400Phase 2Completed
- Sponsor
- Momenta Pharmaceuticals
- Start
- Sep 2007
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of m118 in coronary artery disease (CAD) (4 arms), sponsored by Momenta Pharmaceuticals. Primary endpoint: Composite of 30-day Death, MI, Repeat Revascularization, Catheter Thrombus, Stroke, Thrombocytopenia, Bailout Use of Glycoprotein IIb/IIIa Inhibitors and Bleeding. Started Sep 2007; status: completed.
02
Drugs
m118
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00543400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00543400.